Physician profile
Gary Gregerson
NPI 1801834866
$7,577.96
in general payments reported to CMS, 2019-2025
21 companies · $61.79 in 2025
The $61.79 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $67.87 · 2021: $61.16 · 2022: $72.58 · 2023: $5,198 · 2024: $161 · 2025: $61.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,150 · Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,150.00 |
| Food and Beverage | $270.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $5,164.99 | 2023 | Veozah |
| Pfizer INC. | $1,814.65 | 2019 | |
| Abbvie INC. | $194.32 | 2019-2025 | |
| Boston Scientific Corporation | $67.87 | 2020 | |
| Lilly USA, LLC | $66.39 | 2019-2024 | Zepbound |
| Novo Nordisk INC | $56.72 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $28.32 | 2019 | |
| Exact Sciences Corporation | $21.27 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $19.30 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $18.89 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.86 | 2024 | Voquezna |
| Organon LLC | $16.91 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $16.10 | 2019 | |
| Daiichi Sankyo INC. | $15.70 | 2019 | |
| Lucid Diagnostics INC. | $15.30 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $15.11 | 2024 | |
| Acella Pharmaceuticals, LLC | $14.79 | 2025 | NP Thyroid 60 |
| Janssen Pharmaceuticals, INC | $13.47 | 2023 | Spravato |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gregerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.